Clinical Report: Myopathy Associated with Atorvastatin and Almonertinib
Overview
This case study highlights a probable drug-drug interaction leading to myopathy in an 89-year-old male patient taking atorvastatin and almonertinib. The patient's serum creatine kinase levels significantly elevated, indicating myopathy, which normalized after discontinuation of the medications.
Background
Statin-induced myopathy is a notable adverse effect, particularly in patients on multiple medications that may interact, especially those that inhibit CYP3A4. Almonertinib, a third-generation EGFR-TKI, is a substrate of CYP3A4, raising concerns about its concurrent use with statins like atorvastatin. Understanding these interactions is crucial for managing patients with cardiovascular disease and cancer, as they often require complex medication regimens.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
An 89-year-old male patient developed myopathy after starting atorvastatin alongside almonertinib.
Serum creatine kinase levels rose to 2,103 U/L, indicating significant muscle damage.
Myopathy was likely due to a drug-drug interaction between atorvastatin and almonertinib.
Discontinuation of both medications resulted in normalization of CK levels.
Alternative cholesterol-lowering agents, such as PCSK9 inhibitors, may be safer for patients on almonertinib.
Clinical Implications
Healthcare providers should be vigilant about the risk of myopathy in patients taking atorvastatin and almonertinib concurrently. Consideration of alternative lipid-lowering therapies may be warranted to mitigate this risk, especially in elderly patients or those on polypharmacy.
Conclusion
This case underscores the importance of monitoring for myopathy in patients receiving atorvastatin and almonertinib, highlighting the need for careful medication management in complex clinical scenarios.
Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on...
A new report released by the Union for International Cancer Control shows that people exposed over the long term to fine particulate matter (PM2.5) (such as vehicle exhaust, wildfires, wood burning) h...
